Dr. Ann Arvin, M.D

NPI: 1982748463
Total Payments
$17,096
2019 Payments
$525.00
Companies
3
Transactions
14

Payment Breakdown by Category

Consulting$16,423 (96.1%)
Travel$565.07 (3.3%)
Food & Beverage$108.00 (0.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $16,423 9 96.1%
Travel and Lodging $565.07 3 3.3%
Food and Beverage $108.00 2 0.6%

Top Paying Companies

Company Total Records Latest Year
GlaxoSmithKline, LLC. $12,633 7 $0 (2017)
Merck Sharp & Dohme Corporation $2,363 5 $0 (2018)
PFIZER INC. $2,100 2 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2019 $525.00 1 PFIZER INC. ($525.00)
2018 $262.50 1 Merck Sharp & Dohme Corporation ($262.50)
2017 $16,308 12 GlaxoSmithKline, LLC. ($12,633)

All Payment Transactions

14 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
06/03/2019 PFIZER INC. XELJANZ (Drug) Consulting Fee Cash or cash equivalent $525.00 General
Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT
04/02/2018 Merck Sharp & Dohme Corporation V212 (Biological) Consulting Fee Cash or cash equivalent $262.50 General
Category: VACCINE
11/23/2017 GlaxoSmithKline, LLC. Consulting Fee Cash or cash equivalent $7,820.00 General
11/23/2017 GlaxoSmithKline, LLC. Travel and Lodging In-kind items and services $204.00 General
11/23/2017 GlaxoSmithKline, LLC. Food and Beverage In-kind items and services $54.00 General
10/13/2017 GlaxoSmithKline, LLC. Consulting Fee Cash or cash equivalent $4,140.00 General
09/08/2017 GlaxoSmithKline, LLC. Travel and Lodging In-kind items and services $204.00 General
09/08/2017 GlaxoSmithKline, LLC. Travel and Lodging In-kind items and services $157.07 General
09/08/2017 GlaxoSmithKline, LLC. Food and Beverage In-kind items and services $54.00 General
07/21/2017 Merck Sharp & Dohme Corporation V212 (Biological) Consulting Fee Cash or cash equivalent $350.00 General
Category: VACCINE
06/05/2017 PFIZER INC. Consulting Fee Cash or cash equivalent $1,575.00 General
05/31/2017 Merck Sharp & Dohme Corporation V212 (Biological) Consulting Fee Cash or cash equivalent $700.00 General
Category: VACCINE
04/24/2017 Merck Sharp & Dohme Corporation V212 (Biological) Consulting Fee Cash or cash equivalent $350.00 General
Category: VACCINE
01/30/2017 Merck Sharp & Dohme Corporation V212 (Biological) Consulting Fee Cash or cash equivalent $700.00 General
Category: VACCINE

About Dr. Ann Arvin, M.D

Dr. Ann Arvin, M.D is a Pediatric Infectious Diseases healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982748463.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Arvin, M.D has received a total of $17,096 in payments from pharmaceutical and medical device companies, with $525.00 received in 2019. These payments were reported across 14 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($16,423).

Practice Information

  • Specialty Pediatric Infectious Diseases
  • Location Stanford, CA
  • Active Since 02/16/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 2080P0208X
  • Entity Type Individual
  • NPI Number 1982748463

Products in Payments

  • V212 (Biological) $2,363
  • XELJANZ (Drug) $525.00

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Infectious Diseases Doctors in Stanford